Active Filter(s):
Details:
Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.
Lead Product(s): Antibody Drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 10, 2022
Details:
The positive interim results are particularly significant given all patients in this cohort had late-stage prostate cancer and had failed multiple anti-cancer treatments (including taxanes), in addition to surgeries and radiation, prior to entering the DEP® cabazitaxel trial.
Lead Product(s): Cabazitaxel
Therapeutic Area: Oncology Product Name: DEP Cabazitaxel
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2021
Details:
The composition of matter patent covers a DEP® dendrimer conjugated to multiple cabazitaxel drug molecules via a particular releasable linker. DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®).
Lead Product(s): Cabazitaxel
Therapeutic Area: Oncology Product Name: DEP Cabazitaxel
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Viraleze administered nasally reduced viral load by more than 99.9% in the lungs and trachea of animals challenged with the SARS-CoV-2 virus, compared to saline-control.
Lead Product(s): Astodrimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Viraleze
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
Details:
Starpharma has launched its antiviral nasal spray VIRALEZE™ into the UK via a large national pharmacy chain to support COVID-19 efforts. VIRALEZE™ was developed, manufactured and registered by Starpharma.
Lead Product(s): Astodrimer sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Viraleze
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma’s proprietary DEP® technology.
Lead Product(s): Dendrimer based antibody drug conjugates
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 12, 2021
Details:
Based on discussions with regulators, the company expects to be able to expedite approval of a SPL7013 nasal spray by leveraging existing nonclinical and clinical data of Starpharma’s currently approved and marketed products.
Lead Product(s): Astodrimer sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SPL7013
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-21 (coronavirus), which causes COVID-19.
Lead Product(s): Astodrimer sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020